Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
grade A 117.78 2.42% 2.78
UTHR closed up 2.42 percent on Friday, May 29, 2020, on 56 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Flat
Historical UTHR trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
20 DMA Support Bullish 2.42%
Inside Day Range Contraction 2.42%
20 DMA Support Bullish 0.83%
Multiple of Ten Bearish Other -0.57%
Upper Bollinger Band Touch Strength -0.57%
MACD Bearish Signal Line Cross Bearish 0.18%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Chemistry Biotechnology Infectious Diseases Chemical Compounds Organic Compounds Pulmonary Arterial Hypertension Alcohols Neuroblastoma Pulmonary Hypertension Hepatitis C Treprostinil Cac All Share Index Chronic And Life Threatening Conditions Prostaglandins

Is UTHR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 124.78
52 Week Low 74.31
Average Volume 622,230
200-Day Moving Average 93.38
50-Day Moving Average 104.95
20-Day Moving Average 115.22
10-Day Moving Average 117.71
Average True Range 4.13
ADX 33.76
+DI 27.27
-DI 16.97
Chandelier Exit (Long, 3 ATRs ) 112.39
Chandelier Exit (Short, 3 ATRs ) 117.05
Upper Bollinger Band 121.07
Lower Bollinger Band 109.38
Percent B (%b) 0.72
BandWidth 10.15
MACD Line 3.26
MACD Signal Line 3.82
MACD Histogram -0.5539
Fundamentals Value
Market Cap 5.12 Billion
Num Shares 43.5 Million
EPS 8.62
Price-to-Earnings (P/E) Ratio 13.66
Price-to-Sales 3.17
Price-to-Book 2.91
PEG Ratio -0.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 123.62
Resistance 3 (R3) 122.97 120.38 122.64
Resistance 2 (R2) 120.38 118.89 120.70 122.32
Resistance 1 (R1) 119.08 117.98 119.73 119.73 121.99
Pivot Point 116.49 116.49 116.82 116.81 116.49
Support 1 (S1) 115.19 115.00 115.84 115.84 113.57
Support 2 (S2) 112.60 114.09 112.92 113.24
Support 3 (S3) 111.30 112.60 112.92
Support 4 (S4) 111.95